Azer-Cel Shows 89% Stable or Improved Disability Scores in Progressive MS Phase 1
TGTX sits 96% above its 52-week low of $26.76 on light trading volume (0.1× avg).
Summary
TG Therapeutics reported Phase 1 data for azer-cel in progressive multiple sclerosis at MSTORonto2026, with 89% of evaluable participants showing stable or improved disability scores at Day 90. The CAR-T therapy was given to 26 people and showed an encouraging initial safety profile, with no dose-limiting toxicities and no high-grade CAR-T associated toxicities. This is early-stage, small-N data, but it puts a second pipeline asset beyond the company's BRIUMVI franchise into the clinic with a clean safety readout. The commercial story remains BRIUMVI, which posted $227.7M in U.S. revenue in Q2 2026 with full-year guidance around $950M; azer-cel is optionality, not near-term revenue.
At the time of this announcement, TGTX was trading at $52.44 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $8B. The 52-week trading range was $26.76 to $59.30. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Reuters.